
Phase 3 CAMZYOS® (mavacamten) Study Confirms Efficacy and Safety for Obstructive Hypertrophic Cardiomyopathy
Bristol Myers Squibb (NYSE: BMY) has announced new long-term follow-up data from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study. This data evaluates the efficacy and safety of CAMZYOS®…











